Cargando…

Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case–control study in China

OBJECTIVES: To investigate the changes in serum myeloperoxidase (MPO), interleukin (IL)-17A and heparin-binding EGF-like growth factor (HB-EGF) levels before and after percutaneous coronary intervention (PCI), and to evaluate the associations of MPO, IL-17A and HB-EGF levels with the 1-year restenos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hua, Zhang, Hongmei, Yang, Ying, Yang, Xuezhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651712/ https://www.ncbi.nlm.nih.gov/pubmed/33158827 http://dx.doi.org/10.1136/bmjopen-2020-039405

Ejemplares similares

Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy
por: Csató, Gábor, et al.
Publicado: (2022)

Heavy Coronary Calcium Mimicking In-Stent Restenosis
por: Park, Jeong-Hwan, et al.
Publicado: (2011)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management
por: Abouelnour, Amr, et al.
Publicado: (2022)

Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
por: Wańha, Wojciech, et al.
Publicado: (2022)

High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis
por: Jiang, Hua, et al.
Publicado: (2016)

Prevalence, predictors, and management for balloon uncrossable or undilatable lesions in patients undergoing percutaneous coronary intervention with in-stent restenosis chronic total occlusion
por: Wang, Yong, et al.
Publicado: (2023)

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis
por: Fu, Yuan, et al.
Publicado: (2022)

Coronary Angioscopy Findings before and after Excimer Laser Coronary Angioplasty for Bare-Metal Stent In-Stent Restenosis
por: Masuda, Shinichiro, et al.
Publicado: (2019)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

Coronary stent restenosis and the association with allergy to metal content of 316L stainless steel
por: D, Slodownik, et al.
Publicado: (2018)

Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease
por: Xi, Hongfei, et al.
Publicado: (2023)

The Predictive Value of the Perivascular Adipose Tissue CT Fat Attenuation Index for Coronary In-stent Restenosis
por: Qin, Bin, et al.
Publicado: (2022)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis
por: Demyanets, Svitlana, et al.
Publicado: (2014)

Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty
por: Sajadian, Mostafa, et al.
Publicado: (2018)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
por: Joo, Hyung Joon, et al.
Publicado: (2018)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention
por: Zhang, Gai, et al.
Publicado: (2020)

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention
por: Alexandrescu, Dan-Mihai, et al.
Publicado: (2021)

In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways
por: Pelliccia, Francesco, et al.
Publicado: (2023)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
por: Hou, Ling, et al.
Publicado: (2023)

Albumin to globulin ratio was associated with in‐stent restenosis and revascularization events after percutaneous coronary intervention
por: Zhang, Rui, et al.
Publicado: (2022)

Unusually aggressive immature neo-intimal hyperplasia causing in-stent restenosis
por: Keir, McCutcheon, et al.
Publicado: (2017)

Calculating the overall risk of within-stent restenosis after multilesion percutaneous coronary intervention
por: Parviz, Yasir, et al.
Publicado: (2013)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention: Retraction
Publicado: (2020)

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
por: Zheng, Guo-Hua, et al.
Publicado: (2012)

Arterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention
por: Prskalo, Zrinko, et al.
Publicado: (2016)

SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention
por: Zhou, Liang, et al.
Publicado: (2017)

Efficacy of intramuscular methyl prednisolone in preventing restenosis after coronary artery stenting with bare-metal stainless steel stent: a double-blind, randomised, controlled clinical trial
por: Namdari, M, et al.
Publicado: (2011)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation
por: Yi, Ming, et al.
Publicado: (2022)

Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
por: Ahmed, Talha, et al.
Publicado: (2022)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention
por: Lv, Lizhi, et al.
Publicado: (2019)

The Early Predictive Value of Circulating Monocytes and Eosinophils in Coronary DES Restenosis
por: Li, Shumei, et al.
Publicado: (2022)

Usefulness of Platelet Distribution Width and Fibrinogen in Predicting In-stent Restenosis With Stable Angina and Type 2 Patients With Diabetes Mellitus
por: Chai, Dayang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5b0kcp0olkhu91ngl6b24jl9i2